The release of 5-HT in terminal areas of the rodent brain is regulated by 5-HT 1B receptors. Here we examined the role of 5-HT 1B receptors in the control of 5-HT output and ®ring in the dorsal raphe nucleus (DR), median raphe nucleus (MnR) and forebrain of the rat in vivo. The local perfusion (30±300 mM) of the selective 5-HT 1B receptor agonist CP-93,129 to freely moving rats decreased 5-HT release in the DR and more markedly in the MnR. Likewise, 300 mM CP-93,129 reduced 5-HT output in substantia nigra pars reticulata, ventral pallidum, lateral habenula and the suprachiasmatic nucleus. 
The release of serotonin in nerve endings is regulated by somatodendritic 5-HT 1A and terminal 5-HT 1B/1D receptors. The stimulation of 5-HT 1A receptors in the midbrain dorsal (DR) or median (MnR) raphe nucleus suppresses ®ring of serotonergic cells Aghajanian 1986, 1987; VanderMaelen et al. 1986; Sinton and Fallon 1988) and release of 5-HT in terminal areas of the brain (Hutson et al. 1989; Sharp et al. 1989a; Bonvento et al. 1992; Adell et al. 1993; Bosker et al. 1994; Kreiss and Lucki 1994; Casanovas et al. 1997) . Several studies in vivo have shown that 5-HT 1B/1D receptor agonists reduce 5-HT release in nerve endings (Sharp et al. 1989b; Hjorth and Tao 1991; Roberts et al. 1997 Roberts et al. , 2000 Gaster et al. 1998; Hertel et al. 1999; Knobelman et al. 2000) . There is also evidence that indicates the presence of 5-HT 1B and 5-HT 1D receptors in the DR whose activation decreases the local release of 5-HT (Starkey and Skingle 1994; Davidson and Stamford 1995; Pin Äeyro et al. 1995; Moret and Briley 1997) . The role that 5-HT 1B receptors play in the control of serotonergic cell ®ring is more controversial. Thus, initial observations showed that 5-HT 1B/1D receptor agonists failed to alter spontaneous 5-HT cell ®ring in the DR Aghajanian 1986, 1987; Pin Äeyro et al. 1996; Sprouse et al. 1997) . This led to the conclusion that 5-HT 1B receptors are not involved in the regulation of 5-HT neuron ®ring activity. Nevertheless, other work has described that higher doses of 5-HT 1B receptor agonists enhanced 5-HT cell ®ring in the DR (Evrard et al. 1999; Hertel et al. 2001 ) and the MnR (Sinton and Fallon 1988) , although this effect has not been characterized pharmacologically.
Besides its role as an autoreceptor that regulates the release of 5-HT, the 5-HT 1B subtype has also been described as heteroreceptor located on non-serotonergic terminals of the brain where it controls the release of other neurotransmitters such as glutamate (Boeijinga and Boddeke 1993; Tanaka and North 1993; Li and Bayliss 1998) , GABA (Stanford and Lacey 1996; Chadha et al. 2000) , acetylcholine (Maura and Raiteri 1986; Bolan Äos-Jime Ânez et al. 1994) and dopamine , among others. Consistent with the notion that 5-HT 1B receptors exist as auto-or heteroreceptors to regulate the release of neurotransmitters, they have been visualized predominantly in nerve terminals or pre-terminal axons (Boschert et al. 1994; Sari et al. 1997 Sari et al. , 1999 Riad et al. 2000) . In contrast, a high density of 5-HT 1B receptor mRNA has been detected in the raphe nuclei of the rat (Voigt et al. 1991; Bruinvels et al. 1994; Doucet et al. 1995) .
Until recently it has been impossible to discriminate pharmacologically between 5-HT 1B and 5-HT 1D receptors because of the lack of selective compounds. At present, a few 5-HT receptor agonists such as CP-93,129 (Macor et al. 1990 ; Koe et al. 1992a,b) and CP-94,253 (Koe et al. 1992c) have been shown to display high af®nity and a good selectivity for the 5-HT 1B subtype. In addition, some selective 5-HT 1B receptor antagonists such as SB-224289 (Gaster et al. 1998; Roberts et al. 1998 ) have been developed.
In the present study we assessed the role of 5-HT 1B receptors in the control of 5-HT release and 5-HT cell ®ring in the rat brain. Speci®cally, we examined the effects of the local application of the selective 5-HT 1B receptor agonists CP-93,129 on the 5-HT output in the DR, MnR and various projection areas of both nuclei in the forebrain. In the second part of the study we examined the role of 5-HT 1B receptors in the control of serotonergic cell ®ring in the DR and MnR. Given that CP-93,129 does not cross the blood±brain barrier, we used its propoxy derivative CP-94,253, which is a selective and brain-penetrant 5-HT 1B receptor agonist and therefore can be administered systemically. Finally, we examined whether or not electrophysiological changes paralleled changes in 5-HT release. For this purpose CP-94,253 was administered intravenously to chloral hydrate anesthetized rats and 5-HT ef¯ux was measured in both raphe nuclei and three projection areas of the forebrain. A preliminary account of some of the ®ndings of the present study was presented to the 30th Annual Meeting of the Society for Neuroscience .
Materials and methods

Animals
Male Wistar rats weighing 280±350 g were supplied by Iffa-Credo (Lyon, France). The rats were group housed in a room controlled for temperature (22^28C) and a 12-h lighting cycle (lights on at 07 : 00). Food and water were available ad libitum. All experimental procedures were approved by the local Institutional Animal Care and Use Committee and conducted in strict compliance with the European Communities Council Directive on`Protection of Animals Used in Experimental and Other Scienti®c Purposes' of 24 November 1986 (86/609/EEC). All efforts were made to minimize animal suffering and to reduce the number of animals used.
Chemicals and drugs
All the reagents were of analytical grade and obtained from Merck (Darmstadt, Germany). The 5-HT 1B receptor agonist CP-93,129 was purchased from Tocris Cookson Ltd (Bristol, UK). The 5-HT 1A receptor agonist 8-OH-DPAT and the 5-HT 1A receptor antagonist WAY-100635 were from RBI (Natick, MA, USA). Citalopram hydrobromide, the 5-HT 1B receptor agonist CP-94,253 and the 5-HT 1B receptor antagonist SB-224289 were generously donated by H. Lundbeck A/S (Copenhagen-Valby, Denmark), P®zer (Groton, CT, USA) and SmithKline Beecham Pharmaceuticals (Harlow, Essex, UK), respectively. For local administration through dialysis probes, each of the drugs was dissolved in arti®cial CSF. Concentrated solutions were stored at 2808C, and working solutions were prepared immediately before the experiments. For systemic administration drugs were dissolved in saline, except for SB-224289, which was suspended in 1% sucrose and gently warmed. All the doses administered are referred as free base. Groups of rats were perfused with arti®cial CSF or injected with vehicle to serve as control for the local or systemic administration of drugs.
Intracerebral microdialysis
Procedures of microdialysis probe construction were described previously (Adell and Artigas 1998) . Concentrically designed probes were made up of a 25-gauge stainless steel cannula (A-M Systems, Carlsborg, WA, USA) into which a capillary fused silica tube (Polymicro Technologies, Phoenix, AZ, USA) was inserted. Dialysis membranes of 5000 Da molecular weight cut-off were made from hollow cuprophan ®bers (252 mm outer diameter). On the day preceding dialysis experiment, rats were anesthetized with an i.p. injection of 60 mg/kg sodium pentobarbital and placed in a stereotaxic frame (David Kopf, Tujunga, CA, USA). Microdialysis probes with a 1.5-mm-long exchange surface were implanted using the following coordinates (in mm) from bregma and the top of the skull, according to Paxinos and Watson (1986) After an initial 1 h sample of dialysate was discarded, four samples were collected to establish stable baseline levels of 5-HT. In some experiments microdialysis was carried out in anesthetized animals. For this purpose dialysis probes were implanted as described above and 24-h later animals were anesthetized with chloral hydrate (400 mg/kg, i.p.) and supplemental doses were injected to maintain anesthesia throughout the experiment. At the completion of dialysis experiments, rats were given an overdose of sodium pentobarbital and a fast green solution was perfused through the dialysis probes to stain the surrounding tissue. The brain was removed, frozen, and sliced free hand at the appropriate levels using a surgical blade. Data were excluded if the probe track was not in the targeted site.
Biochemical measurements
Dialysate samples were analyzed for 5-HT by a HPLC method described previously (Adell and Artigas 1998) . Brie¯y, 5-HT was separated on a 3-mm octadecylsilica (ODS) column (7.5 cm Â 0.46 cm; Beckman, San Ramon, CA, USA) and detected amperometrically with a Hewlett-Packard 1049 detector (Palo Alto, CA, USA) set at an oxidation potential of 0.6 V. The detection limit for 5-HT was estimated to be around 1 fmol/sample. Quanti®cation of 5-HT was carried out by an external standard method using a Nelson Turbochrom Navigator (Perkin-Elmer, San Jose, CA, USA).
Single unit recordings
Single unit extracellular recordings were performed as previously described (Sawyer et al. 1985; Celada et al. 1996) . Rats were anesthetized with chloral hydrate (400 mg/kg, i.p.) and the femoral vein was cannulated to administer drugs and additional anesthetic (chloral hydrate, 80 mg/kg) when needed. The animals were then placed in a stereotaxic frame. All wound margins and points of contact between the animal and the stereotaxic apparatus were impregnated with a 5% lidocaine solution. Body temperature was maintained at 37^18C with a heating pad. The atlanto-occipital membrane was punctured to allow drainage of the CSF. A 4 Â 4 mm recording hole was drilled over the lambda and the sagittal sinus was ligated, cut and re¯ected.
Recording electrodes were fabricated from 2.0 mm outer diameter capillary glass (WPI, Saratosa, FL, USA) pulled on a Narishige PE-2 pipette puller (Narishige Scienti®c Instruments, Tokyo, Japan) and ®lled with 2 m NaCl and few crystals of pontamine sky blue. The electrode impedance was lowered between 4 and 10 MV by passing 500 ms 150 V DC pulses through the electrode (Grass Stimulation Model S-48).
Single unit extracellular recordings were ampli®ed with a Neurodata IR283 (Cygnus Technology Inc., Delaware Water Gap, PA, USA), post-ampli®ed and ®ltered with a Cibertec ampli®er (Madrid, Spain) and computed on-line through a DAT 1401plus interface system using Spike2 software (Cambridge Electronic Design, Cambridge, UK). Data were also recorded on magnetic audiotape for off-line recording if necessary.
Descents were carried out along the midline and 5-HT neurons were recorded at 5.90^0.25 mm (DR) and 8.33^0.23 mm (MnR) below the brain surface. Serotonergic neurons were identi®ed according to previously described electrophysiological criteria Aghajanian 1977, 1982) . They exhibited a regular ®ring rate with frequencies of 0.3±3.2 Hz, and 2±5 ms bior triphasic extracellular waveform. After recording stable baseline spontaneous activity for at least 5 min, CP-94,253 was administered i.v. at increasing doses every minute. The selective 5-HT 1A receptor agonist 8-OH-DPAT was injected at the end of experiments to further verify the serotonergic nature of recorded neurons. Experiments were ®nalized by passing current through the electrode to leave a blue spot at the recording site. Recordings were made from one cell in each animal. At the end of each experiment rats were given a lethal overdose of anesthetic and perfused with 10% buffered formalin. Brains were removed, sectioned and stained with Neutral Red for histological veri®cation of the recording sites.
Data analysis
Unless otherwise speci®ed, results are expressed as mean^SEM.
In dialysis experiments, the average of four fractions before drug administration was de®ned as 100% (baseline), and the subsequent perfusate levels were expressed as a percentage of the pre-treatment baseline level. These values as well as electrophysiological data were analyzed with a one-or two-way repeated measures anova followed by the Duncan's multiple range test. For all procedures the level of signi®cance was set at p , 0.05. All statistical procedures were performed using the Statistica software for Windows (StatSoft, Tulsa, OK, USA).
Results
Basal values of dialysate 5-HT in the raphe nuclei
In freely moving awake animals the basal values of 5-HT in dialysate samples of DR and MnR in the presence of 1 mm citalopram were 23.9^3.0 fmol/5 mL (n 26) and 33.8^3.0 fmol/5 mL (n 47), respectively. The output of 5-HT in the MnR was signi®cantly higher than that in the DR ( p , 0.05, t-test). In chloral hydrate-anesthetized animals the basal values of 5-HT in dialysate samples of DR and MnR in the presence of 1 mm citalopram were 14.0^1.3 fmol/5 mL (n 9) and 18.4^2.0 fmol/5 mL (n 16), respectively. In both raphe nuclei the output of 5-HT was higher in awake compared to anesthetized animals. However, in the DR this difference did not reach statistical signi®cance.
Effects of CP-93,129 on dialysate 5-HT The compound CP-93,129 exhibits a high af®nity for the 5-HT 1B receptor (K i 8.1 nm; Koe et al. 1992a,b,c) with greater that 100-fold binding selectivity over 5-HT 1D sites (K i 1100 nm; Koe et al. 1992a,b,c) . The effects of the local perfusion of CP-93,129 on dialysate 5-HT in DR and MnR of awake animals are depicted in Fig. 1 . In the DR, anova analysis revealed signi®cant effects of concentration of CP-93,129 ( p , 0.05), time ( p , 0.001) and the interaction between both factors ( p , 0.001). Post-hoc comparisons showed that 100 mm and 300 mm of the 5-HT 1B agonist decreased extracellular 5-HT to a similar extent, i.e. ,60% of control values at the offset of perfusion. In the MnR, anova analysis revealed signi®cant effects of concentration of CP-93,129 ( p , 0.001), time ( p , 0.001) and the interaction between both factors ( p , 0.001). Post-hoc comparisons showed that 30 mm CP-93,129 decreased dialysate 5-HT to a ,70% whereas at 100 mm and 300 mm, this compound evoked a maximal reduction of dialysate 5-HT to a ,30% of control values. Overall, the reduction in 5-HT release following CP-93,129 was signi®cantly more marked in the MnR compared to the DR ( p , 0.05). The continuous perfusion of arti®cial CSF throughout the experiment did not modify the release of 5-HT in both raphe nuclei. To rule out the participation of 5-HT 1A receptors in the decrease of the 5-HT release induced by CP-93,129, the 5-HT 1A antagonist WAY-100635 Forster et al. 1995) was perfused simultaneously with CP-93,129. WAY-100635, at the concentration of 100 mm, which antagonizes the decrease in 5-HT release produced by 8-OH-DPAT in the MnR (Adell and Artigas 1998), did not affect 5-HT release per se and failed to alter CP-93,129-induced reduction of 5-HT release in the MnR (Fig. 2) .
In order to compare the effects of CP-93,129 in the raphe nuclei and several projection areas, this compound was perfused locally in areas known to be connected with the raphe nuclei, i.e. the lateral habenula and the suprachiasmatic nucleus Moore et al. 1978) and also enriched in 5-HT 1B receptors such as substantia nigra pars reticulata and ventral pallidum (Sari et al. 1999) . As shown in Fig. 3 , the local perfusion of 300 mm CP-93,129 signi®cantly reduced dialysate 5-HT in the four projection areas studied ( p , 0.001) to a similar extent (,35±45% of pre-drug values), which was not signi®cantly different from the effect of the same concentration in the MnR. 
Effects of local SB-224289 and CP-93,129 on dialysate 5-HT
The effects of cumulative concentrations of SB-224289 on dialysate 5-HT in DR and MnR of awake animals are shown in Fig. 4 . At the concentrations tested (1±100 mm) this 5-HT 1B antagonist had no effect on extracellular 5-HT in both nuclei. However, SB-224289 blocked the decrease in 5-HT release in the MnR evoked by CP-93,129 in a concentration-dependent manner ( p , 0.01). Thus, although 100 mm SB-224289 was not suf®cient to block the effect of 50 mm CP-93,129, 200 mm of SB-224289 (which alone did not alter dialysate 5-HT) was able to prevent the effect of 30 mm of CP-93,129 in reducing dialysate 5-HT in the MnR (Fig. 5) .
Effects of CP-94,253 on 5-HT cell ®ring
The compound CP-94,253 exhibits a high af®nity for the 5-HT 1B receptor (K i 2.0 nm; Koe et al. 1992c ) with 25-fold greater binding selectivity over 5-HT 1D sites (K i 49 nm; Koe et al. 1992c) . The basal ®ring rate of 5-HT cells recorded was 1.2^0.3 spikes/s in the DR (n 8) and 0.7^0.2 spikes/s in the MnR (n 7). The effects of cumulative doses of CP-94,253 on the ®ring of two 5-HT neurons in the DR and MnR are shown in Fig. 6 . Overall, the systemic administration of cumulative doses of CP-94,253 (0.05±1.6 mg/kg, i.v.) to chloral hydrate anesthetized rats did not change the ®ring activity of DR 5-HT neurons. In contrast, the same treatment increased signi®-cantly ( p , 0.001) the ®ring rate of 5-HT neurons in the MnR. Post hoc comparisons showed that the effects of cumulative doses 0.2±1.6 mg/kg of CP-94,253 were statistically signi®cant.
The administration of vehicle (0.9% NaCl) did not alter the spontaneous ®ring activity of 5-HT neurons in any of the raphe nuclei (data not shown).
Effects of CP-94,253 on dialysate 5-HT
The effects of the systemic administration of CP-94,253 on dialysate 5-HT in the raphe nuclei and three projection areas of chloral hydrate anesthetized rats are depicted in Fig. 7 . anova analysis revealed signi®cant effects of brain region ( p , 0.01), time ( p , 0.001) and the interaction between both factors ( p , 0.001). When comparisons were established between the corresponding control groups in each region (not shown), anova analysis revealed signi®cant Fig. 7 Effects of the intravenous administration of CP-94,253 (arrows) to chloral hydrate anesthetized rats on dialysate 5-HT in DR (W, n 5), MnR (A, n 4), medial pre-frontal cortex (X, mPFC; n 5), dorsal hippocampus (P, DHPC; n 5) and globus pallidus (B, GP, n 4). For each region a control group (n 4±5) was run in which the rats were injected intravenously with saline (not shown).
Results are mean^SEM and expressed in percentage changes from pre-drug values. The effects of CP-94,253 were signi®cant in MnR, dorsal hippocampus and globus pallidus ( p , 0.01) but not in DR and mPFC. Effects of SB-224289 and CP-94,253 on dialysate 5-HT In order to compare the local effects of 253 in the MnR, a wide range of concentrations of the latter compound (from 30 nm to 300 mm) were perfused through the dialysis probe in the MnR. The results depicted in Fig. 8 show a biphasic effect. Lower concentrations of 300 nm and 3 mm decreased dialysate 5-HT to 74% ( p , 0.01) and 52% ( p , 0.001) of control values, respectively, whereas that of 300 mm increased 5-HT to a 188% ( p , 0.05) of control values. In addition, it was intended to ascertain whether the decrease of 5-HT in the MnR induced by lower concentrations of CP-94,253 was due to an action upon 5-HT 1B receptor. For this purpose SB-224289 was perfused simultaneously with CP-94,253. The concentration of 200 mm SB-224289 did not alter 5-HT release per se, but prevented the effect of 3 mm CP-94,253 (Fig. 9) .
Finally, to determine whether the increase in 5-HT release evoked by the intravenous injection of CP-94,253 resulted from an action upon 5-HT 1B autoreceptors, SB-224289 (5 mg/kg, i.v.) was injected 80 min before CP-94,253 (2 mg/kg, i.v.). The results depicted in Fig. 10 show that, with respect to the control group, 5-HT increased 53% ( p , 0.05) after CP-94,253 and 71% after the combined treatment ( p , 0.001). The systemic injection of SB-224289 also produced a 33% increase of 5-HT over basal values, but this did not reach statistical signi®cance.
Discussion
Previous work has suggested the presence of operational 5-HT 1B receptors in the DR of the rat (Davidson and Stamford 1995; Herva Âs et al. 1998; Stamford et al. 2000; Hertel et al. 2001) . However, until recently, the lack of selective compounds has hampered functional studies on 5-HT 1B receptors. To the best of our knowledge, this is the ®rst study in which the highest selective 5-HT 1B receptor agonists and antagonist available are used to compare in vivo the role of 5-HT 1B receptors in the control of 5-HT cell ®ring and release in the DR and MnR of the rat.
The local perfusion of the selective 5-HT 1B agonist CP-93,129 decreased dialysate 5-HT in the DR and MnR of the rat in a concentration-dependent manner. This agrees with other studies in the raphe nuclei (Davidson and Stamford 1995; Moret and Briley 1997; Hertel et al. 2001) and is coincident to what occurs in projection areas of the forebrain (Sharp et al. 1989b; Hjorth and Tao 1991; Hertel et al. 1999; Knobelman et al. 2000) . The ®nding that the reduction in 5-HT release evoked by CP-93,129 is prevented by concomitant perfusion with SB-224289, but not by WAY-100635, further strengthens an action upon intraraphe 5-HT 1B receptors as observed by others (Davidson and Stamford 1995) . The lower effect of CP-93,129 in the DR compared to the MnR might be accounted for by different ef®cacy and/or density of 5-HT 1B receptors in each nucleus. Previous studies have shown that the 5-HT output in the DR is controlled by 5-HT 1D rather than 5-HT 1B receptors (Davidson and Stamford 1995; Pin Äeyro et al. 1995 Pin Äeyro et al. , 1996 Hertel et al. 2001) . We agree inasmuch as the effects of CP-93,129 in the DR are relatively smaller than those in the MnR. However, in concordance with the present study, Hopwood and Stamford (2001) have shown recently that the reduction of 5-HT output in the MnR is not prevented by the selective 5-HT 1D receptor antagonist BRL 15572. It therefore seems that 5-HT 1B receptors are more important in regulating 5-HT release in the MnR, whereas the role of 5-HT 1D receptors would be more relevant in the DR. The question remains as to the subcellular localization of these receptors. As rightly pointed out by Stamford et al. (2000) , it cannot be assumed that a functional action upon a 5-HT receptor in the raphe nuclei implies a somatodendritic location of the receptor. Immunocytochemical studies have revealed the presence of not only cell bodies and dendrites in the raphe region, but also an intricate meshwork of 5-HT ®bers (Steinbusch 1981) . Furthermore, although less abundant than in forebrain areas, in the raphe region a 40% of 5-HT varicosities and/or terminals has been found (TaoCheng and Zhou 1999) and the 5-HT 1B receptor has been predominantly described in 5-HT terminals (Boschert et al. 1994; Sari et al. 1999) . On the other hand, because the concentration of 5-HT 1B receptor mRNA is similar in both nuclei (Doucet et al. 1995) , our results also suggest that the receptor protein is less expressed in the DR. Some immunocytochemical studies have questioned the presence of the 5-HT 1B receptor protein in the raphe nuclei of the rodent brain (Boschert et al. 1994; Sari et al. 1997 Sari et al. , 1999 . However, a limitation of immunocytochemical techniques is the accessibility of receptor antigenic sites in the plasma membrane and it is possible that the low amount of 5-HT 1B receptors located in the raphe nuclei (albeit entirely functional) is below the detection limit of the technique. The decrease in dialysate 5-HT induced by CP-93,129 was similar in the four projection areas studied and akin to what the same concentration of the compound produced in the MnR. Taking into consideration that the amount of 5-HT 1B receptors in those regions are very different (Bruinvels et al. 1993) , it would appear that the release of 5-HT in terminal areas does not depend on the density of such receptors. However, it must be kept in mind that the majority of the 5-HT 1B receptor labeling in the substantia nigra pars reticulata and ventral pallidum does not correspond to the autoreceptor but to heteroreceptor in terminals of GABAcontaining neurons (Boschert et al. 1994; Sari et al. 1999) . Therefore, this means that the effects of CP-93,129 observed are brought about by a small proportion on 5-HT 1B sites located in 5-HT nerve endings. In contrast to the effects of CP-93,129, the local administration of the selective 5-HT 1B receptor antagonist SB-224289 did not affect dialysate 5-HT in both raphe nuclei. This suggests that endogenous 5-HT does not exert a tonic action on 5-HT 1B autoreceptors in DR and MnR, at least in the conditions of the present study. A lack of effect of SB-224289 on 5-HT release has also been observed in several regions of the brain of rat (Gobert et al. 2000; Herva Âs et al. 2000) and guinea pig . Nevertheless, in the latter work SB-224289 has been described as an inverse agonist in the dentate gyrus of the guinea pig because it increases the output of 5-HT . It thus seems that the increase in 5-HT release evoked by a 5-HT 1B receptor antagonist might depend on the species and the brain region (Barnes and Sharp 1999) .
Unlike CP-93,129 (Macor et al. 1990) , its propoxy derivative CP-94,253 enters readily the brain after systemic administration and thus it could be given intravenously to study the role of 5-HT 1B receptors on 5-HT cell ®ring. Although the pharmacological pro®le of both compounds is similar, the af®nity of CP-94,253 for 5-HT 1B receptors is 4-fold higher than that of CP-93,129 (Koe et al. 1992c) . The systemic administration of CP-94,253 increased the ®ring rate of 5-HT cells in the MnR, but not in the DR up to a cumulative dose of 1.6 mg/kg. This is consistent with previous studies showing that higher doses of non-selective 5-HT 1B receptor agonists increase the discharge rate of 5-HT neurons in the MnR without altering that in the DR of the rat (Sprouse and Aghajanian 1987; Sinton and Fallon 1988) . A recent work also showed that a single 3 mg/kg dose of CP-94,253 enhances 5-HT cell ®ring in the DR of mice and that this effect is prevented in 5-HT 1B receptor knock-out mice (Evrard et al. 1999) , which clearly suggests an action upon 5-HT 1B receptors. It is conceivable that higher doses of the compound than those given in the present work could induce the same effect in the DR of the rat, although species differences might exist. In our present study the increase in the electrophysiological activity of MnR 5-HT neurons parallels the enhanced dialysate 5-HT found in this nucleus. The presence of citalopram in the dialysate precludes a direct comparison between data from microdialysis and single unit recordings. However, it has been indicated that, at low concentration of citalopram in the perfusion¯uid, 5-HT release remains predominantly dependent on depolarization (Tao et al. 2000) . It is thus possible that the increased 5-HT release observed in the present conditions results from enhanced serotonergic cell ®ring. To discern whether the increased 5-HT in the MnR after systemic CP-94,253 was due to an action on 5-HT 1B receptors located within the nucleus or elsewhere, two additional experiments were conducted. First, the compound was perfused through a dialysis probe implanted in the MnR of awake animals. In the lower concentration range (up to 3 mm) CP-94,253 reduced dialysate 5-HT and this effect is blocked by SB-224289, which indicates an activation of local 5-HT 1B autoreceptors, in line with the effects of CP-93,129. In contrast, higher concentrations of CP-94,253 increased 5-HT as observed following systemic administration. Secondly, systemic SB-224289, at a dose known to block 5-HT 1B autoreceptor-mediated effects (Gaster et al. 1998) , failed to prevent the CP-94,253-induced increase in 5-HT release. Thus, the question remains as to whether or not the effect of systemic CP-94,253 on MnR 5-HT is due to its agonism on 5-HT 1B receptors. Previous work with 5-HT 1B receptor knock-out mice attributed the CP-94,253-induced elevation of 5-HT cell ®ring to an action upon 5-HT 1B receptors located outside the raphe which would activate a distal feedback loop (Evrard et al. 1999) . It is conceivable that this also caused the elevated 5-HT in the MnR in the present study. The negligible af®nity of CP-94,253 for other transmitter receptors (Koe et al. 1992c) nearly precludes an unspeci®c action of the compound. The biphasic effect of local CP-94,253 rather suggests actions on different populations of 5-HT 1B receptors. Without ruling out the distal loop alternative, we hypothesize that the increase of 5-HT release (and possibly serotonergic ®ring rate) in the MnR might also be mediated by 5-HT 1B heteroreceptors located in inhibitory neurons impinging upon 5-HT cells. In good accordance with this hypothesis, it has been observed that the sensitivity of 5-HT 1B receptor agonists and antagonists for the 5-HT 1B autoreceptor is ,90 fold higher than that for the 5-HT 1B receptors and 5-HT release 179 heteroreceptor counterpart . Needless to say that further investigation is needed to authenticate this hypothesis.
The systemic administration of CP-94,253 reduced dialysate 5-HT in terminal areas as expected for a 5-HT 1B autoreceptor agonist. This suggests that the local action of CP-94,253 on 5-HT 1B receptors in nerve endings is independent on its simultaneous effect in the cell body areas (increased 5-HT ef¯ux in the MnR and no change in the DR). Furthermore, the CP-94,253-induced decrease in 5-HT observed in the dorsal hippocampus, a region that receives serotonergic innervation predominantly from the MnR (Azmitia and Segal 1978) , is clearly dissociated from an increased ®ring rate and 5-HT release in the MnR. Therefore, it appears that the activation of the terminal autoreceptor overcomes opposing changes in the electrophysiological activity of these 5-HT neurons.
In summary, 5-HT 1B receptors appear to control 5-HT cell ®ring and release in rostral raphe nuclei although these effects are more conspicuous in the MnR compared to the DR. The activation of 5-HT 1B autoreceptors (possibly located on 5-HT nerve endings and/or varicosities within DR and MnR) leads to a reduced release of 5-HT. On the other hand, the effects of higher amounts of 5-HT 1B receptor agonists seems more compatible with the activation of 5-HT 1B heteroreceptors located in inhibitory neurons.
